Big Pharmas remain stuck to the idea of molecular glue degraders. The latest company to see an opportunity is Japan’s Eisai, which has signed a $1.5 billion biobucks pact with SEED Therapeutics for undisclosed neurodegeneration and oncology targets.

大型制药公司仍然坚持分子胶降解剂的想法。最新一家看到机会的公司是日本卫材，该公司与SEED Therapeutics签署了一项价值15亿美元的生物块协议，用于未披露的神经退行性疾病和肿瘤学目标。

The agreement will see Pennsylvania-based SEED take the lead on preclinical work to identity the targets, including E3 ligase selection and picking out the appropriate molecular glue degraders. Eisai will then have exclusive rights to further develop the resulting compounds.

该协议将使总部位于宾夕法尼亚州的SEED牵头开展临床前工作，以确定目标，包括E3连接酶的选择和挑选合适的分子胶降解剂。卫材将拥有进一步开发所得化合物的专有权。

In return, SEED is in line for up to $1.5 billion in potential upfront, preclinical, regulatory and sales-based milestone payments, although the companies didn’t offer a detailed breakdown of the financial details. Should any drugs make it to market, SEED will also receive tiered royalties.

作为回报，SEED将获得高达15亿美元的潜在前期、临床前、监管和基于销售的里程碑付款，尽管这些公司没有提供详细的财务细节。如果任何药物上市，SEED还将获得分级版税。

“SEED has a cutting-edge technology platform to discover a class of molecular-glue target protein degraders, one of the most highlighted modalities in modern drug discovery,” Eisai’s Chief Scientific Officer Takashi Owa, Ph.D., said in the release.

卫材首席科学官Takashi Owa博士在新闻稿中表示：“SEED拥有一个尖端技术平台，可以发现一类分子胶靶蛋白降解剂，这是现代药物发现中最突出的方式之一。”。

Related

相关的

Takeda gets crafty with $1.2B biobucks deal to create molecular glues with Degron

武田狡猾地与Degron达成12亿美元的生物块交易，以制造分子胶

Owa name-checked Celgene’s blockbuster anti-myeloma drug Revlimid as an example of where the “molecular-glue class has been successful in the oncology field,” but said today’s collaboration will “also focus on utilizing this modality in the neurology field.”

Owa name检查了Celgene的重磅抗骨髓瘤药物Revlimid，作为“分子胶类在肿瘤学领域取得成功”的一个例子，但表示今天的合作将“也专注于在神经病学领域利用这种模式”。

Alongside today’s licensing deal, Eisai has led on a $24 million series A-3 funding round for SEED. This is only the round’s first close, according to this morning’s release, with a second close due in the fourth quarter.

除了今天的授权协议，卫材还为SEED领投了2400万美元的a-3轮融资。根据今天上午的新闻稿，这只是本轮的第一次收盘，第二次收盘将在第四节结束。

The biotech said the money will go toward advancing its oral RBM39 degrader into a phase 1 study next year for biomarker-driven cancer indications. This program builds on “Eisai’s pioneering discovery of a class of RBM39 degraders over three decades,” the company noted.

该生物技术公司表示，这笔资金将用于明年将其口服RBM39降解剂推进生物标志物驱动的癌症适应症的第一阶段研究。该公司指出，该计划建立在“卫材三十年来对一类RBM39降解剂的开创性发现”的基础上。

SEED, a subsidiary of cancer therapeutics biotech BeyondSpring, also needs the cash to move forward with its tau degrader program for Alzheimer’s disease, with the aim of submitting a request with the FDA in 2026 to begin human trials. Funds will also be used to scale up its targeted protein degradation platform.

SEED是癌症治疗生物技术BeyondSpring的子公司，也需要资金来推进其阿尔茨海默病tau降解剂计划，目的是在2026年向FDA提交开始人体试验的请求。资金还将用于扩大其目标蛋白质降解平台。

Eisai is only the latest drugmaker keen to paste some molecular glue candidates into its pipeline. Fellow Japanese pharma Takeda signed a $1.2 billion biobucks deal with Degron Therapeutics in May, while Novo Nordisk secured a similar $1.46 billion pact with Neomorph in February.

卫材只是最新一家热衷于将一些分子胶候选物粘贴到其管道中的制药商。日本制药公司武田于5月与Degron Therapeutics签署了一项价值12亿美元的生物美元协议，而诺和诺德于2月与Neomorph签署了一份类似的14.6亿美元协议。

SEED has also been the recipient of Big Pharma attention in the past, with Eli Lilly paying $20 million in upfront cash and equity in 2020 to discover new chemical entities against undisclosed targets.

SEED过去也受到了大型制药公司的关注，礼来公司在2020年支付了2000万美元的预付现金和股权，以发现针对未披露目标的新化学实体。